Company Filing History:
1 out of 2 
1 out of 7 Years Active: 2024
Title: Carmen Salvador Coloma: Innovator in Predicting Cardiotoxicity Risk
Introduction
Carmen Salvador Coloma is a notable inventor based in Valencia, Spain. He has made significant contributions to the field of medical research, particularly in predicting cardiotoxicity risk in cancer patients undergoing anthracyclines chemotherapy. His innovative approach utilizes a combination of circulating microRNAs as biomarkers for this critical health concern.
Latest Patents
Carmen Salvador Coloma holds a patent for an invention titled "Predicting cardiotoxicity risk in cancer patients receiving anthracyclines chemotherapy." This invention outlines an in vitro method for assessing the risk of cardiotoxicity based on the expression levels of a specific set of 10 circulating miRNAs. These include miRNA 16-5p, miRNA 22-3p, miRNA 30b-5p/30c-5p, miRNA 92b-3p, miRNA 148a-3p, miRNA-150-5p, miRNA 192-5p, miRNA 215-5p, miRNA 486-3p/486-5p, and miRNA-4732-3p. The invention also proposes a method for preventing cardiotoxicity by modulating the expression levels of these miRNAs.
Career Highlights
Throughout his career, Carmen has worked with esteemed institutions such as the Fundación Para La Investigación Del Hospital Universitario La Fe De La Comunidad Valenciana and Maastricht University. His work has been pivotal in advancing the understanding of cardiotoxicity in cancer treatment.
Collaborations
Carmen has collaborated with notable colleagues, including David Hervàs Marin and Ana Santaballa Beltràn, who have contributed to his research endeavors.
Conclusion
Carmen Salvador Coloma's innovative work in predicting cardiotoxicity risk represents a significant advancement in cancer treatment. His contributions are vital for improving patient outcomes and enhancing the safety of chemotherapy protocols.